Background: The disease burden caused by recently identified respiratory viruses like HCoV-NL63 is unknown. Objectives: We determined the burden of disease due to HCoV-NL63 infections using the population-based PRI.DE cohort of children under the age of 3 with lower respiratory tract infections (LRTIs). Study design: In total 1756 respiratory samples, from hospitalized children or children who visited the outpatient clinic, were tested for HCoV-NL63. Sampling covered a period of 2 years and the frequency of infection in different years was compared to other Western European studies that tested for this virus in 2 or more consecutive years. Results: Sixty-nine samples were HCoV-NL63 positive, 35 were with high loads, and of these 25 were single HCoV-NL63 infections. Based on the number of children with high HCoV-NL63 infection and no additional infection, the overall annual incidence in outpatients was 7 per 1000 children per year (95% confidence interval (CI) 3-13 per 1000 children per year), which can be extrapolated to an absolute number of 16,929 visits to the physician due to an HCoV-NL63 infection in Germany per year. The estimated hospitalization rate is 22 per 100,000 children (95% CI: 7-49 per 100,000 children per year). This number reflects 522 HCoV-NL63 children in Germany per year. A large year-to-year difference in HCoV-NL63 infection frequency was observed. Combining these data with those of other studies in Western Europe revealed that HCoV-NL63 infections follow a 2-year inter-epidemic period with peaks of infection in the winters of (p < 0.0001). Conclusions: HCoV-NL63 infection in children below 3 years of age often requires a visit to the physician in an outpatient clinic, especially during peak-years, but hospitalizations are relatively infrequent.
Background
Coronavirus infections of humans are mostly restricted to the respiratory tract. The human coronaviruses were first identified in the mid 1960s (HCoV-229E and HCoV-OC43 1-3 ), but in 2003, 2004 and 2005 , three new human coronavirus species have been identified (SARS-CoV, HCoV-NL63 and HCoV-HKU1, respectively 4-7 ). HCoV-NL63 was first described in a child with bronchiolitis in Ams-Abbreviations: LRTI, lower respiratory tract infection; HCoV, human coronavirus; CI, confidence intervals; NPS, nasopharyngeal secretions; RSV, respiratory syncytial virus; PIV, human parainfluenza virus.
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E-mail address: c.m.vanderhoek@amc.uva.nl (L. van der Hoek). terdam, the Netherlands, 6 but it soon turned out that HCoV-NL63 infection occurs frequently in children, [8] [9] [10] is observed around the globe (reviewed in Ref. 11) , and infection is associated with croup and acute otitis media. 10, 12 
Objectives
The disease burden caused by respiratory viruses is huge in children, which led to the development of vaccines that can be used in young children. For the new respiratory viruses the disease burden is unknown, therefore we determined the burden of disease due to HCoV-NL63 infections in the population-based study (PRI.DE study) on children under the age of 3 with lower respiratory tract infections (LRTI). The PRI.DE study covers 2 years, and children were recruited in the north, east, south and west of Germany at pediatric practices and referral children's hospitals. 13 This study design ascertained representation of the German children as 95% of them have a pediatrician, and -in case of hospitalization -over 95% of them are referred to a children's hospital.
Study design

Participants, materials and laboratory testing
Paediatric practices (outpatients) and hospitals (inpatients) from Hamburg, Bochum, Freiburg and Dresden participated in the study. 13 Children with clinical signs of apnoea (under the age of 6 months), laryngotracheitis (croup), bronchitis, bronchiolitis, or pneumonia were included in the study. Signs and symptoms were defined according to Denny and Clyde. 14 Recruitment covered the period from November 1999 to October 2001. Nasopharyngeal secretions (NPS) were collected in a standardized manner as described. 13 Of the 3.677 NPS that were collected within the PRI.DE study, half were randomly assigned to this study. The randomization was performed via a program generating random numbers in order to distribute samples equally between 2 different laboratories. The ethics committee of each participating center approved the study protocol and written informed consent was obtained from parents of all children. RNA was extracted and tested for RSV, PIV-1, PIV-2, PIV-3, influenza viruses and HCoV-NL63 by hexaplex PCR and real-time RT-PCR as described. 10 Samples collected in France (winter 2003/2004) and the Netherlands (2002 till 2005) that were screened for HCoV-NL63 were analyzed as described. 6, 15 Furthermore, data from literature were included only for those studies that screened consecutive years in Western Europe and in which each year the sample selection criteria did not change. Thus a year-to-year difference is a reflection of periodicity of infection.
Incidence calculations
Incidence rates were estimated based on the PRI.DE results, 13 i.e. an incidence of lower respiratory tract infections of 28.7 per 100 children per year seen by a doctor, and using HCoV-NL63 infection rates obtained from our analysis. The PRI.DE population at risk was determined using numbers of well-baby visits which are attended regularly. 16 These figures were used to estimate total numbers of LRTI cases and HCoV-NL63-LRTI cases in the German pediatric population, based on German census data (population size on December 31st, 1999; data from Statistisches Bundesamt, Statistisches Jahrbuch 2001).
Hospitalization rates
Figures for the total number of hospitalizations in the German pediatric population were determined by applying the observed proportion of HCoV-NL63-related LRTI cases in the PRI.DE study hospitals to the total number of hospitalizations in 1999 in Germany (data from Statistisches Bundesamt, Statistisches Jahrbuch 2002; interpolation of age groups 0-1 year and 1-5 years).
Confidence intervals
95% confidence intervals (CIs) for incidence rates and hospitalization rates were obtained by calculating exact 97.5% CIs from the binomial distribution for infection rates and combining these with 97.5% CIs for the hospitalization rate due to LRTI or annual LRTI incidence rate. 16 
Results
Burden of disease
The PRI.DE study is a prospective population-based study. One can thus calculate the annual incidence rate and the total national disease burden attributable to HCoV-NL63-related LRTIs in children under the age of 3 years. This calculation uses national census data (outpatients) and national hospital statistics (inpatients). In total 1756 PRI.DE samples are included in the present study, representing 48% of the total number of samples that were collected. To confirm whether the HCoV-NL63-tested samples were representative for the entire PRI.DE study (which comprised 3677 children), we checked collection dates, study region, age, male/female distri- bution, diagnosis, virus detection and determined that in none of these categories there was any bias in sample selection (shown in Tables 1 and 2). Of the 1756 children, 685 visited the outpatient clinic, and 1071 were hospitalized. In total we detected 69 HCoV-NL63 infections (3.9%). Of these, 38 were children visiting the outpatient clinic (5.5% of outpatients) and 31 children were hospitalized (2.9% of all hospitalized patients). Similar to what was published previously 10 a high frequency of croup was noted in the HCoV-NL63 infected children (26.1% of all HCoV-NL63 positives, p < 0.0001 two-sided Fisher's exact test).
The peak of infection was centered around the winter months of each year (Fig. 1) . When we include all HCoV-NL63 infections (n = 69) to calculate the burden of disease, a total of 16 visits to the physician per 1000 children per year were calculated, corresponding to 37,841 visits to a physician per year in Germany. The hospitalization rate is 85 per 100,000 children per year, corresponding to 2022 hospitalizations per year in Germany. However, during double infections it is debatable whether one or the combination of the two viruses causes the disease encountered. Double infections with HCoV-NL63 and a second respiratory virus were frequently found (49.3%). Furthermore we observed a very strong association between a high HCoV-NL63 viral load and single infec- tions, and in case of double infections the viral load was low (p < 0.0001, Wilcoxon's two sample test). 10 To ascertain that the disease burden is calculated for HCoV-NL63 infections only and not influenced by infections with another respiratory virus we included only those infections which were not accompanied by a second respiratory virus (n = 35). Furthermore we included merely HCoV-NL63 infections with high viral load, which was arbitrarily defined as samples with more than 10,000 copies per ml (n = 25). Using these restrictions we calculated that the annual incidence of HCoV-NL63 infection was 7 per 1000 children per year (95% confidence interval (CI) 3-13 per 1000 children per year), reflecting an absolute number of 16,929 visits to the physician in Germany per year (95% CI: 7255-31,440). The estimated hospitalization rate due to HCoV-NL63 alone is 22 per 100,000 children (95% CI: 7-49 per 100,000 children per year). This number reflects 522 children in Germany per year (95% CI: 166-1163), which is a conservative estimate.
Periodicity of infection
The winter season is the preferred season for infection by HCoV-NL63, yet large year-to-year differences in frequency is apparent. As shown in Fig. 1 , infection by HCoV-NL63 is limited to a small percentage in the first year of the study, whereas in the winter of 2000/01 the frequency reaches levels above 10%. This indicates that there is an inter-epidemic period, 17 (Table 3 and 15, 18, 19 ), indicating that the frequency is high every other year. To verify whether the inter-epidemic period is 2 years we combined all our data and the published data on HCoV-NL63 screenings during 2 or more consecutive years in Western Europe 6, [19] [20] [21] [22] [23] Fig. 2 . Percentage HCoV-NL63 positive samples in Western Europe, the included studies are described in Table 3 . A year is defined from August to July. *: significantly higher percentage compared to years 99/00, 01/02 and 03/04, p < 0.0001, Chi-square test.
We found no significant differences when comparing 1999/2000, 2001/2002 and 2003/2004 (rates 1.5%/1.1%/1.6%, p = 0.92, Chi-square test with 2df), but modest differences were noticeable when comparing 2000/2001, 2002/2003 and 2004/2005 (rates 6.4%/3.8%/3.8%, p = 0.003, Chi-square test with 2df).
Discussion
In Germany paediatricians are available for all children and they are consulted instead of general practitioners for primary care. Therefore, sampling in paediatric practices provides the opportunity to collect a representative patient set that reflects the population of German children that are ill but not hospitalized. Most studies that have looked at the frequency of HCoV-NL63 infection in patients with respiratory infections have focused exclusively at hospitalized patients. In the PRI.DE study it is possible to investigate the frequency of infection in both groups: those hospitalized and those visiting the paediatric clinic (outpatients). In a previous study we noticed that HCoV-NL63 infection is observed more frequently in outpatients, 10 and here we calculated that it reflects almost 17,000 visits to the paediatrician each year in Germany, whereas less than 600 children under the age of 3 years need to be hospitalized.
There are only 2 previous studies that calculated the incidence of HCoV-NL63 infection, one from Hong Kong and one from Nashville, USA. 12, 24 The Hong Kong study noticed high numbers of hospitalizations due to HCoV-NL63 infection (210 hospital admissions per 100,000 children ≤6 years of age) whereas we estimate 22 hospitalizations per 100,000 children below the age of 3. The difference in age of the test populations is unlikely to explain the difference. We think that other reasons are more significant. In the Hong Kong study all HCoV-NL63-children were included regardless of the viral load in the NPA, or the presence of a second infection. Furthermore, only a single year was monitored in Hong Kong, and we noticed that the incidence of HCoV-NL63 displays year-to-year differences with a 3-4 times higher rate in uneven winters in Western Europe. We did not include any double infections and HCoV-NL63 infections with low viral load, to diminish the chance that children who are ill due to another respiratory virus infection are counted. In addition, it cannot be ruled out that we even missed some double infections since our samples were not tested for all respiratory pathogens (e.g. hMPV, human bocavirus, and rhinoviruses).
The Nashville study included children with LRTI from several years and a high incidence of HCoV-NL63 in the 6-23 months age group was observed: 12.3 HCoV-NL63 associated LRTIs per 1000 children, although the number of samples that were tested was small (only 5 positives of the 119 samples analyzed). 12 These data are in concordance with our findings as most of the children in their study were not hospitalized, therefore the incidence numbers are comparable to what we noticed for outpatients (7 per 1000 children).
The periodicity of infection that we observed is not unexpected. Already in the mid-1970s Monto & Lim described high infection rates with HCoV-OC43 in the years 1966, 1968 and 1969, but low numbers in 1967. 25 Actually many childhood diseases tend to vary in frequency between years. These oscillations are often of a regular nature, tending to rise as a function of susceptible persons. 17 We In our study we tested for HCoV-NL63. Taking into account that infection by HCoV-OC43, HCoV-229E, and HCoV-HKU1 can also result in LRTI, 26, 27 the incidence numbers for coronavirus infection are probably several folds higher than the numbers we present for just HCoV-NL63 infections. It would be of great interest to determine the incidence of the other coronaviruses in the sample set tested for HCoV-NL63.
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